GleamWall
中文EN

RMTI ROCKWELL MEDICAL, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1041024 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.0%
TTM net income YoY-2.5%
TTM EPS YoY95.2%
Revenue 3-yr CAGR-3.5%
Net income 3-yr CAGR—

Margins

Gross margin18.1%
Operating margin-7.1%
Net margin-7.8%
FCF margin1.1%
EBITDA margin-4.6%

Returns

ROE-16.1%
ROA-9.9%
ROIC (approx.)-12.8%
Asset turnover1.27x

Leverage & solvency

Liabilities / assets42.0%
Debt / equity0.27x
Current ratio2.47x
Interest coverage-4.56x

Cash quality & payout

Operating cash flow / net income-0.47x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$19.12M$17.78M$17.34M$18.35M$15.93M$16.07M$18.91M$24.66M
Cost of revenue$16.01M$14.54M$14.44M$14.47M$13.65M$13.57M$15.87M$21.03M
Gross profit$3.11M$3.24M$2.90M$3.88M$2.27M$2.50M$3.04M$3.63M
R&D expense$114,000$40,000—$0$0$0$0$1,000
SG&A expense$3.80M$3.69M$3.81M$3.74M$3.33M$3.28M$3.69M$3.31M
Operating income-$2.22M-$1.06M-$1.48M-$398,000-$1.58M-$1.35M-$1.36M-$519,000
Interest expense$282,000$281,000$282,000$286,000$285,000$276,000$277,000$289,000
Net income-$2.32M-$1.17M-$1.60M-$554,000-$1.75M-$1.49M-$1.51M-$756,000
EBITDA-$1.82M-$661,000-$969,000$148,000-$1.18M-$949,000-$821,000$24,000
EPS (basic)-0.59-0.34-0.04—-0.49-0.48-0.04—
EPS (diluted)——-0.04—-0.05-0.05-0.04—
Weighted avg. shares (diluted)3.97M3.96M39.42M—3.60M3.43M34.11M—
Balance sheet
Cash & equivalents$10.63M$10.52M$9.61M$10.71M$13.61M$12.48M$11.39M$15.66M
Short-term investments———$14.29M———$5.94M
Receivables$9.80M$8.30M$8.82M$8.14M$8.33M$8.08M$9.67M$8.29M
Inventory$2.94M$2.82M$3.06M$3.42M$3.96M$4.16M$5.04M$5.78M
Current assets$37.17M$36.36M$36.94M$38.16M$37.51M$31.61M$33.03M$37.03M
PP&E, net$4.91M$4.62M$4.33M$4.63M$4.95M$5.13M$5.39M$5.79M
Goodwill$921,000$920,000$921,000$921,000$921,000$921,000$921,000$921,000
Intangibles$9.24M$9.38M$9.52M$9.66M$9.79M$9.93M$10.07M$10.21M
Total assets$57.08M$56.53M$57.42M$57.15M$57.49M$52.62M$53.96M$59.21M
Current liabilities$15.07M$11.17M$9.87M$9.58M$9.58M$10.95M$11.21M$14.09M
Short-term debt$2.83M$1.77M$707,000$0————
Long-term debt$6.22M$7.24M$8.21M$8.83M$8.74M$8.65M$8.56M$8.47M
Total debt$9.05M$9.00M$8.91M$8.83M$8.74M$8.65M$8.56M$8.47M
Total liabilities$23.95M$21.44M$21.57M$20.16M$20.47M$22.22M$22.44M$26.62M
Shareholders' equity$33.13M$35.09M$35.86M$36.98M$37.02M$30.41M$31.52M$32.59M
Net debt-$1.58M-$1.52M-$695,000-$1.89M-$4.87M-$3.83M-$2.83M-$7.19M
Shares outstanding3.97M39.72M39.47M3.94M3.94M3.44M34.26M34.06M
Cash flow statement
Operating cash flow-$1.53M$2.08M-$167,000$2.29M-$1.31M$1.84M-$3.49M$865,000
Capital expenditure$722,000$617,000$425,000$86,000$229,000$164,000$63,000$395,000
Free cash flow-$2.25M$1.46M-$592,000$2.21M-$1.54M$1.68M-$3.55M$470,000
Investing cash flow$1.76M-$487,000-$122,000-$4.13M-$4.31M-$103,000-$1,000-$332,000
Financing cash flow-$118,000-$683,000-$813,000-$1.06M$6.74M-$650,000-$783,000$2.79M
Depreciation & amortization$400,000$400,000$511,000$546,000$400,000$400,000$539,000$543,000
Stock-based compensation$391,000$403,000$479,000$457,000$532,000$382,000$445,000$382,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.